ALL
Pharma in China
Pharma Experts
Market News
Products Guide
Brand Story
-
Imugene says HER-Vaxx cancer vaccine induces 50% ORR in stomach cancer trial
July 06, 2021Imugene reported updated Phase II results for HER-Vaxx on Monday, saying that adding the experimental B-cell peptide immunotherapy vaccine to chemotherapy led to an overall response rate (ORR) of 50% in certain patients with gastric cancer. -
Imugene ‘encouraged’ by data for HER2 vaccine in gastric cancer
December 26, 2018Australian biotech Imugene says its HER2 vaccine hit the mark in a phase 1b trial, setting up a phase 2 study that will start recruiting patients in the new year.....
Pharma Sources Insight January 2025
